Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug

Dutch biotech Azafaros raised €132 million (approximately $146-148 million) in an oversubscribed Series B funding round led by Jeito Capital and Forbion Growth.12345

The capital will fund parallel Phase 3 clinical trials for their lead oral candidate, nizubaglustat, which targets rare lysosomal storage disorders—specifically Niemann-Pick disease type C (NPC) and GM1/GM2 gangliosidoses.1245

Nizubaglustat is a brain-penetrant therapy with a dual mode of action and is designed to offer disease-modifying potential in neuro-metabolic diseases.24

European regulatory authorities have granted Azafaros important designations and cleared the company to initiate global Phase 3 studies, expected to start in 2025.5

The financing will also help expand Azafaros' pipeline into additional indications, leveraging the company's expertise in treating rare, severe neurological diseases.24

This Series B round comes during a turbulent period for the rare disease biotech sector, highlighting Azafaros' achievements and investor confidence in their approach.24

Sources:

1. https://www.bioworld.com/articles/720106-azafaros-raises-132m-in-series-b-for-parallel-phase-iii-trials

2. https://www.biospace.com/business/azafaros-raises-150m-to-target-rare-neuro-metabolic-diseases

3. https://www.investorsinhealthcare.com/articles/category/news/the-netherlands-azafaros-secures-e132m-in-oversubscribed-series-b/

4. https://www.globenewswire.com/news-release/2025/05/13/3079737/0/en/Jeito-Capital-leads-EUR-132-million-oversubscribed-Series-B-financing-in-Azafaros-to-advance-Phase-3-clinical-programs-of-innovative-therapies-in-rare-inherited-neuro-metabolic-dis.html

5. https://www.businesswire.com/news/home/20250512102563/en/Azafaros-Secures-%E2%82%AC-132M-in-Oversubscribed-Series-B-Financing-to-Advance-Phase-3-Clinical-Programs-of-Innovative-Therapies-in-Lysosomal-Storage-Disorders